TrialNature communications2025

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

Xichun Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.